University of Missouri School of Medicine MU Health School of Medicine
News Divider

Compound improves cardiac function in mice with genetic heart defect


MU study recognized by American Heart Association

Congenital heart disease is the most common form of birth defect, affecting one out of every 125 babies, according to the National Institutes of Health. Researchers from the University of Missouri recently found success using a drug to treat laboratory mice with one form of congenital heart disease, hypertrophic cardiomyopathy — a weakening of the heart caused by abnormally thick muscle. By suppressing a faulty protein, the researchers reduced the thickness of the mice’s heart muscles and improved their cardiac functioning.

Maike Krenz, MD, has been studying hypertrophic cardiomyopathy for nearly 10 years, soon after a gene was discovered in 2001 that linked the disease to the genetic conditions Noonan syndrome and LEOPARD syndrome. In Noonan and LEOPARD syndromes, the thickened heart muscle of hypertrophic cardiomyopathy is caused by a defective Shp2 protein, created by a mutation in the gene PTPN11.

Krenz

“Previously, not much has been known about the biochemistry behind Shp2 and hypertrophic cardiomyopathy,” said Krenz, an assistant professor of medical pharmacology and physiology at the MU School of Medicine, and a researcher at MU’s Dalton Cardiovascular Research Center. “We know the thickened heart muscle is sick and doesn’t work properly, and we know a defective Shp2 protein can cause heart muscle to thicken. However, to create an effective treatment, we need to know what Shp2 is doing inside the heart to cause the defect.”

To test whether they could interrupt the heart’s hypersensitivity to growth signals, the researchers gave a chemical compound, PHPS1, to mice with a mutated gene that produces the defective Shp2 protein.

“Not only did the compound reduce the thickness of the heart muscle to the size of normal heart muscle, but it also improved the cardiac pumping of the heart,” Krenz said. “That’s important because people with hypertrophic cardiomyopathy have an increased risk of sudden cardiac death. If we could develop an effective treatment for the disease and improve patients’ heart function, we could save many people’s lives.”

Because of the role Shp2 plays in signaling heart growth, Krenz believes the research could be translated in the future into improved treatments for other types of heart disease, such as damage caused by heart attack.

Krenz presented the research findings, “Inhibition of Shp2’s Phosphatase Activity Ameliorates Cardiac Hypertrophy in LEOPARD Syndrome Models,” at the American Heart Association’s Scientific Sessions conference in November 2013, where it received the Outstanding Research Award in Pediatric Cardiology. LEOPARD syndrome is related to Noonan syndrome and receives its name from an acronym for multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth and deafness.

Click here to download a high resolution portrait of Krenz.



Missouri Health News Network

Divider

News and Events

Dermatology Gala Gala To Celebrate Five Decades Of Dermatology At MU
Dermatology residency program began in 1963

HIV MU Researchers Discover Protein's Ability To Inhibit HIV Release
TIM-family proteins also play role in Ebola and other viral infections

McAndrew $2.4 Million Gift Funds Endowed Chair in Cancer Research
Support inspired by experience with cancer center and student at MU

Lai MU Researchers Find Gene Therapy Protects Mice from Heart Condition
The condition is a leading cause of death for those with Duchenne muscular dystrophy

White Coat Ceremony MU's Expanded Medical Class Receives White Coats at Ceremony
Event marks start of professional journey for 104 students

Belden Interactive E-Book Aims to Improve Electronic Health Records
E-book provides guidelines for usability of EHRs

Delafontaine Tulane Cardiovascular Researcher Named School of Medicine Dean
Patrice Delafontaine, MD, is accomplished physician-scientist, educator, administrator

Frederick Fraunfelder, MD Fraunfelder Joins MU School of Medicine as Chair of Ophthalmology
Fraunfelder specializes in corneal disease, cancers of the eye and laser surgery

Karl D. Nolph, MD In Memoriam: Karl D. Nolph, MD
Nephrology leader was pioneer in the field of dialysis

Class of 2014 Race Could Be a Factor in Head and Neck Cancer Survival Rates
Prognosis has not improved for African-Americans




Media Relations
University of Missouri Health System
One Hospital Drive, DC028.00
Columbia, MO 65212
24/7 on-call pager: (573) 876-0708

Mary Jenkins
jenkinsmg@health.missouri.edu
(573) 882-7299

Jeff Hoelscher
hoelscherj@health.missouri.edu
(573) 884-1608

Derek Thompson
thompsonder@health.missouri.edu
(573) 882-3323


Web Communications
University of Missouri Health System
One Hospital Drive, MA204G, DC018.00
Columbia, MO 65212
(573) 884-0298

Rich Gleba
glebar@health.missouri.edu
(573) 884-0298

Laura Gerding, APR
gerdingla@health.missouri.edu
(573) 882-9193

Velvet Hasner
hasnerv@health.missouri.edu
(573) 884-1115

Mike Muin
muinm@health.missouri.edu
(573) 884-7541



Printer Friendly
Follow us on Twitter!   Facebook   YouTube Videos  
Website created and maintained by the Office of Communications.
Contact the MU School of Medicine.
Revised: February 04, 2014 - Copyright © 2013 - The Curators of the University of Missouri System.
All rights reserved. DMCA and other copyright information. An equal opportunity/affirmative action institution.